The dominant genic male sterility （DGMS） gene CDMs399-3 derived from a spontaneous mutation in the line 79-399-3 of spring cabbage （Brassica oleracea var. capitata L.）, has been successfully applied in hybrid seed...The dominant genic male sterility （DGMS） gene CDMs399-3 derived from a spontaneous mutation in the line 79-399-3 of spring cabbage （Brassica oleracea var. capitata L.）, has been successfully applied in hybrid seed production of several cabbage cultivars in China. During the development of dominant male sterility lines in cabbage, the conventional identification of homozygous male-sterile plants （CDMs399-3/CDMs399-3） is a laborious and time-consuming process. For marker-assisted selection （MAS） of the gene CDMs399-3 transferred into key spring cabbage line 397, expressed sequence tag-simple sequence repeats （EST-SSR） and SSR technology were used to identify markers that were linked to CDMs399-3 based on method of bulked segregant analysis （BSA）. By screening a set of 978 EST-SSRs and 395 SSRs, a marker BoE332 linked to the CDMs399-3 at a distance of 3.6 cM in the genetic background of cabbage line 397 were identified. 7 homozygons male-sterile plants in population P1170 with 20 plants were obtained finally via MAS of BoE332. Thus, BoE332 will greatly facilitate the transferring of the gene CDMs399-3 into the key spring cabbage line 397 and improve the application of DGMS in cabbage hybrid breeding.展开更多
This paper discusses complete binary trees as chromosomes of Genetic Algorithm (GA), and proposes the concept of dominant and recessive genes. On the base of it, a new crossover operator with the selective ability was...This paper discusses complete binary trees as chromosomes of Genetic Algorithm (GA), and proposes the concept of dominant and recessive genes. On the base of it, a new crossover operator with the selective ability was designed. Finally experimental results are presented.展开更多
AIM To investigate the therapeutic potential of tesevatinib(TSV),a unique multi-kinase inhibitor currently in Phase Ⅱ clinical trials for autosomal dominant polycystic kidney disease(ADPKD),in well-defined rodent mod...AIM To investigate the therapeutic potential of tesevatinib(TSV),a unique multi-kinase inhibitor currently in Phase Ⅱ clinical trials for autosomal dominant polycystic kidney disease(ADPKD),in well-defined rodent models of autosomal recessive polycystic kidney disease(ARPKD).METHODS We administered TSV in daily doses of 7.5 and 15 mg/kg per day by I.P.to the well characterized bpk model of polycystic kidney disease starting at postnatal day(PN) 4 through PN21 to assess efficacy and toxicity in neonatal mice during postnatal development and still undergoing renal maturation.We administered TSV by oral gavage in the same doses to the orthologous PCK model(from PN30 to PN90) to assess efficacy and toxicity in animals where developmental processes are complete.The following parameters were assessed:Body weight,total kidney weight;kidney weight to body weight ratios;and morphometric determination of a cystic index and a measure of hepatic disease.Renal function was assessed by:Serum BUN;creatinine;and a 12 h urinary concentrating ability.Validation of reported targets including the level of angiogenesis and inhibition of angiogenesis(active VEGFR2/KDR) was assessed by Western analysis.RESULTS This study demonstrates that:(1) in vivo pharmacological inhibition of multiple kinase cascades with TSV reduced phosphorylation of key mediators of cystogenesis:EGFR,ErbB 2,c-Src and KDR;and(2) this reduction of kinase activity resulted in significant reduction of renal and biliary disease in both bpk and PCK models of ARPKD.The amelioration of disease by TSV was not associated with any apparent toxicity.CONCLUSION The data supports the hypothesis that this multi-kinase inhibitor TSV may provide an effective clinical therapy for human ARPKD.展开更多
基金supported by the National Science and Technology Ministry of China (2008BADB1B02 and 2009BADB8B03)the Core Research Budget of the Non-profit Governmental Research Institution (ICS, CAAS) (1610032011011)+1 种基金the China Agriculture Research System (CARS-25)the National High Technology Research and Development Program of China (863 Program, 2012AA100101)
文摘The dominant genic male sterility （DGMS） gene CDMs399-3 derived from a spontaneous mutation in the line 79-399-3 of spring cabbage （Brassica oleracea var. capitata L.）, has been successfully applied in hybrid seed production of several cabbage cultivars in China. During the development of dominant male sterility lines in cabbage, the conventional identification of homozygous male-sterile plants （CDMs399-3/CDMs399-3） is a laborious and time-consuming process. For marker-assisted selection （MAS） of the gene CDMs399-3 transferred into key spring cabbage line 397, expressed sequence tag-simple sequence repeats （EST-SSR） and SSR technology were used to identify markers that were linked to CDMs399-3 based on method of bulked segregant analysis （BSA）. By screening a set of 978 EST-SSRs and 395 SSRs, a marker BoE332 linked to the CDMs399-3 at a distance of 3.6 cM in the genetic background of cabbage line 397 were identified. 7 homozygons male-sterile plants in population P1170 with 20 plants were obtained finally via MAS of BoE332. Thus, BoE332 will greatly facilitate the transferring of the gene CDMs399-3 into the key spring cabbage line 397 and improve the application of DGMS in cabbage hybrid breeding.
文摘This paper discusses complete binary trees as chromosomes of Genetic Algorithm (GA), and proposes the concept of dominant and recessive genes. On the base of it, a new crossover operator with the selective ability was designed. Finally experimental results are presented.
基金Supported by The PKD research program is provided by the Children’s Research Institute,the Lillian Goldman Charitable Trust,Ellsworth FamilyChildren’s Foundation of Children’s Hospital and Health System of Wisconsin
文摘AIM To investigate the therapeutic potential of tesevatinib(TSV),a unique multi-kinase inhibitor currently in Phase Ⅱ clinical trials for autosomal dominant polycystic kidney disease(ADPKD),in well-defined rodent models of autosomal recessive polycystic kidney disease(ARPKD).METHODS We administered TSV in daily doses of 7.5 and 15 mg/kg per day by I.P.to the well characterized bpk model of polycystic kidney disease starting at postnatal day(PN) 4 through PN21 to assess efficacy and toxicity in neonatal mice during postnatal development and still undergoing renal maturation.We administered TSV by oral gavage in the same doses to the orthologous PCK model(from PN30 to PN90) to assess efficacy and toxicity in animals where developmental processes are complete.The following parameters were assessed:Body weight,total kidney weight;kidney weight to body weight ratios;and morphometric determination of a cystic index and a measure of hepatic disease.Renal function was assessed by:Serum BUN;creatinine;and a 12 h urinary concentrating ability.Validation of reported targets including the level of angiogenesis and inhibition of angiogenesis(active VEGFR2/KDR) was assessed by Western analysis.RESULTS This study demonstrates that:(1) in vivo pharmacological inhibition of multiple kinase cascades with TSV reduced phosphorylation of key mediators of cystogenesis:EGFR,ErbB 2,c-Src and KDR;and(2) this reduction of kinase activity resulted in significant reduction of renal and biliary disease in both bpk and PCK models of ARPKD.The amelioration of disease by TSV was not associated with any apparent toxicity.CONCLUSION The data supports the hypothesis that this multi-kinase inhibitor TSV may provide an effective clinical therapy for human ARPKD.
